Co-prescribing of interacting medications with DOACs decreased slightly over a five-year period (P for trend < 0.001), though interactions with SSRIs/SNRIs remained relatively unchanged.
Cross-Sectional (n=19,196)
Yes
What are the five-year trends in potential drug interactions with DOACs in patients with atrial fibrillation?
While overall potential drug interactions with DOACs have slightly decreased, co-prescription with SSRIs/SNRIs remains common and requires increased prescriber awareness.
p-value: p=< 0.001
BACKGROUND: Co-prescribing medications that can interact with direct-acting oral anticoagulants (DOACs) may decrease their safety and efficacy. The aim of this study was to examine the co-prescribing of such medications with DOACs using the Australian national general practice dataset, MedicineInsight, over a five-year period. METHODS: We performed five sequential cross-sectional analyses in patients with atrial fibrillation (AF) and a recorded DOAC prescription. Patients were defined as having a drug interaction if they had a recorded prescription of an interacting medication while they had had a recorded prescription of DOAC in the previous six months. The sample size for the cross-sectional analyses ranged from 5333 in 2014 to 19,196 in 2018. RESULTS: for trend < 0.001. During this period, the most frequent interacting class of medication recorded as having been prescribed with DOACs was selective serotonin/serotonin and norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants, followed by non-steroidal anti-inflammatory drugs (NSAIDs), calcium channel blockers (CCBs) and amiodarone. CONCLUSIONS: Overall, potential drug interactions with DOACs have decreased slightly over the last five years; however, the rate of possible interaction with SSRIs/SNRIs has remained relatively unchanged and warrants awareness-raising amongst prescribers.
Bezabhe et al. (Thu,) conducted a cross-sectional in Atrial fibrillation (n=19,196). Direct-acting oral anticoagulants (DOACs) was evaluated on Potential drug interactions (co-prescribing of interacting medications with DOACs) (p=< 0.001). Co-prescribing of interacting medications with DOACs decreased slightly over a five-year period (P for trend < 0.001), though interactions with SSRIs/SNRIs remained relatively unchanged.